Complement C5 mAb in the Treatment of Anti-GBM Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Autoimmune Diseases

Interventions

DRUG

Eculizumab

eculizumab 900mg iv. per week for 4 weeks, then 1200mg every two weeks for week 5 to. week 11

Trial Locations (1)

Peking University First Hospital, Beijing

All Listed Sponsors

lead

Peking University First Hospital

OTHER